| Name | Title | Contact Details |
|---|
Modern lifestyles and persistent near vision utilization cause a majority of patients to experience the reduced visual acuity and painful symptoms of eye misalignment – headaches, eye strain, neck and shoulder pain, motion sickness and dry eye sensation. Neurolens addresses common binocular vision issues using a three-step process. Step one is efficiently identifying patient symptomology using a basic online symptom screener that every patient can complete in minutes. This information goes directly to the Neurolens Measurement Device, Gen 2—or NMD2—ready for step two, which is accurately and objectively measuring the patient`s level of misalignment. The NMD2 is an objective, accurate and repeatable way to measure eye misalignment as small as 0.01 Prism Diopters. Most importantly, step three is correcting eye misalignment with a proven lens solution. Neurolenses address binocular vision issues by providing a contoured prism lens design that gradually delivers more prism in the lens corridor from distance to near. Neurolenses are proven to have a profound impact on a patient`s visual clarity and comfort. In fact, 93% of patients responded positively to wearing Neurolenses. Over 81% of patients suffering from chronic daily headaches reported their symptoms were substantially reduced or basically gone after wearing Neurolenses for 90 days. Neurolens—recognized in 2022 as one of the 30 fastest growing private companies in the healthcare industry by Inc. Magazine—is confident that appropriately addressing growing binocular vision issues will become a standard of care in this industry, unlocking dramatic patient outcomes and practice growth.
Beam One is a Denver, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Tko Surgical is a Beaverton, OR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Osiris Therapeutics, Inc. is a leading stem cell company focused on developing and marketing products to treat medical conditions in the inflammatory, autoimmune, orthopedic and cardiovascular areas. Osiris’ stem cell products have significant therapeutic potential because of their ability to regulate inflammation, promote tissue regeneration and prevent pathological scar formation. In Biosurgery, we harness the ability of cells and novel constructs to promote the body`s natural healing. The goals are to improve surgical outcomes and offer better treatment options for patients and physicians. We like a challenge, so the focus is in areas where we believe we can have a significant impact. Difficult indications and challenging cases are targeted. Osiris has been studying tissue engineering since the beginning, and its dedicated team conducted groundbreaking research in the field. The work in bone led to the development of the successful product Osteocel, now owned by NuVasive Inc. Now, application of these technologies is being expanded beyond bone, to soft tissues, such as cartilage and tendon, and also wound healing.
John R. Dwyer, Jr., JD, serves as the Chief Financial Officer and General Counsel of Telcare, Inc. Mr. Dwyer served as Principal of CodeRyte, Inc. He served as an Executive Vice President of Doctors Health, Inc. and also served as its Chief Financial Officer for 2 years. He served as a Principal of Graham, Hamilton & Dwyer, Inc. (“GHD“). He served as Chief Executive Officer of e-MEDx. He served as Chief Operating Officer of Active Health Management. He served as Chief Executive Officer of Vetcentric, a specialty on-line pharmacy. Mr. Dwyer served at Diametrics, Inc., where he served as President of California-based high technology Company. Mr. Dwyer began his professional career as an Attorney with Arent, Fox, Kintner, Plotkin & Kahn, the fifth largest law firm in Washington, D.C., where he focused on transactions in the health care and telecommunications industries. He serves as the Chairman of Redbricks.com, LLC. He serves on the Boards of a number of private and not-for-profit organizations including Earth Conservation Corp. He serves as a Director of the Trust for America's Health. He serves on the Executive Council of Leaders Engaged against Alzheimer's Disease (LEAD). He serves as a Director of USAgainstAlzheimer's. He served as the Chairman of Telcare, Inc. and serves as its Director. He served as a Director of CodeRyte, Inc. Mr. Dwyer served as a Member of the Obama Administration's HHS transition team and has played an active role in the HHS, FDA, and Commerce transition and staffing plans of the Administration. He co-founded the first political action committee focused on a particular disease, the Alzheimer's Action PAC. Mr. Dwyer is a frequent Speaker on financing and regulatory issues of critical importance to emerging health technology companies. He has spoken on health information issues, business risks associated with the FDA approval process, and patent insurance at a variety of forums including the BIO/CEO and AdvaMed annual conferences. Mr. Dwyer is a graduate of Marquette University and the Cornell University Law School.